Trials that use: Log-rank test
New to this method? Read the tutorial →
368 results
- CLEOPATRAIndependent statistical analysis of CLEOPATRA, the randomized phase 3 trial of pertuzumab plus trastuzumab and docetaxel versus placebo plus trastuzumab and docetaxel in previously untreated HER2-positive metastatic breast cancer.
- Clinical Trial to Assess the Efficacy and Safety of ‘Immuncell-LC’ With Temozolomide in Newly Diagnosed Glioblastoma of Korea: Complete Statistical AnalysisIndependent statistical analysis of Clinical Trial to Assess the Efficacy and Safety of 'Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of Korea: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a): Complete Statistical AnalysisIndependent statistical analysis of CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a): primary endpoint results, effect estimate with confidence interval, sample-size…
- CodeBreaK 200Independent statistical analysis of CodeBreaK 200, a randomized phase 3 trial comparing AMG 510 (sotorasib) with docetaxel in KRAS G12C-mutated advanced or metastatic NSCLC, including progression-free survival, hazard ratios, confidence intervals, log-rank…
- Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.: Complete Statistical AnalysisIndependent statistical analysis of Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck: Complete Statistical AnalysisIndependent statistical analysis of Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck: primary endpoint results, effect estimate with…
- Combination Chemotherapy With or Without Rituximab in Treating Participants With Stage III-IV Classic Hodgkin Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Combination Chemotherapy With or Without Rituximab in Treating Participants With Stage III-IV Classic Hodgkin Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer: Complete Statistical AnalysisIndependent statistical analysis of Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- COMET-1Independent statistical analysis of COMET-1, the randomized phase 3 trial of cabozantinib versus prednisone in men with metastatic castration-resistant prostate cancer previously treated with docetaxel and abiraterone or MDV3100.
- COMET-2Independent statistical analysis of COMET-2, a randomized phase 3 trial comparing cabozantinib with mitoxantrone plus prednisone in men with previously treated symptomatic castration-resistant prostate cancer.
- COMMANDER HFIndependent statistical analysis of A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery…
- Comparing Efficacy and Safety of Stivant (AryoGen Bevacizumab) Versus Avastin in Metastatic Colorectal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Comparing Efficacy and Safety of Stivant (AryoGen Bevacizumab) Versus Avastin in Metastatic Colorectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Comparison of IV Topotecan/Docetaxel to Docetaxel Alone in Second-Line Stage IIIB/IV Non-Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Comparison of IV Topotecan/Docetaxel to Docetaxel Alone in Second-Line Stage IIIB/IV Non-Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Comparison of Two Steroid Regimens to Prevent Transplant Rejection After Corneal Transplant (DMEK): Complete Statistical AnalysisIndependent statistical analysis of Comparison of Two Steroid Regimens to Prevent Transplant Rejection After Corneal Transplant (DMEK): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Comparison of Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Adults With Brain Metastases From Non-Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Comparison of Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Adults With Brain Metastases From Non-Small Cell Lung Cancer: primary endpoint results, effect estimate…
- COMPETEIndependent statistical analysis of Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03049189).
- ComPLETIndependent statistical analysis of Comparing Peripherally Inserted Central Catheters to Long Peripheral Catheters in Pediatrics: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- CONFIRMIndependent statistical analysis of Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.: primary endpoint…
- CONTACT-03Independent statistical analysis of CONTACT-03, a randomized phase 3 trial of atezolizumab plus cabozantinib versus cabozantinib alone in participants with advanced renal cell carcinoma after immune checkpoint inhibitor treatment.
- Convalescent Plasma vs. Standard Plasma for COVID-19: Complete Statistical AnalysisIndependent statistical analysis of Convalescent Plasma vs. Standard Plasma for COVID-19: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04344535).
- Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma: Complete Statistical AnalysisIndependent statistical analysis of Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- COPPSIndependent statistical analysis of COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Acebilustat Sub-Protocol: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04662060).
- COU-AA-301Independent statistical analysis of COU-AA-301, a randomized phase 3 trial of abiraterone acetate in castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy, covering overall survival, progression, PSA response, trial design, and statistical…
- COV-BARRIERComplete statistical analysis of the COV-BARRIER phase 3 trial of baricitinib plus standard of care versus placebo plus standard of care in participants with COVID-19, including trial design, endpoints, statistical methodology, reported…
- COVACTAIndependent statistical analysis of the randomized phase 3 COVACTA trial evaluating tocilizumab versus placebo in patients with severe COVID-19 pneumonia, including endpoint definitions, reported treatment effects, confidence intervals, p-values, and statistical methodology.
- CRISTALLOIndependent statistical analysis of A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT…
- Cryoanalgesia vs. Epidural in the Nuss Procedure: Complete Statistical AnalysisIndependent statistical analysis of Cryoanalgesia vs. Epidural in the Nuss Procedure: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02721017).
- Daily Isoniazid to Prevent Tuberculosis in Infants Born to Mothers With HIV: Complete Statistical AnalysisIndependent statistical analysis of Daily Isoniazid to Prevent Tuberculosis in Infants Born to Mothers With HIV: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Delirium Treatment With Acupuncture in Internal Medicine Departments: Complete Statistical AnalysisIndependent statistical analysis of Delirium Treatment With Acupuncture in Internal Medicine Departments: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03398928).
- DESTINY-Breast04Independent statistical analysis of DESTINY-Breast04, a randomized phase 3 trial of trastuzumab deruxtecan versus investigator's choice for HER2-low breast cancer. Includes the reported progression-free survival analysis, trial design, statistical methodology, interpretation, and…
- DESTINY-Breast06Independent statistical analysis of DESTINY-Breast06 (NCT04494425), a randomized phase 3 trial comparing trastuzumab deruxtecan with investigator's choice chemotherapy in HER2-low, hormone receptor-positive, advanced or metastatic breast cancer.
- DIGESTIndependent statistical analysis of Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01285557).
- DIRECTComplete statistical analysis of DIRECT (NCT00252694), a randomized phase 3 trial of candesartan in type 2 diabetes, including trial design, diabetic retinopathy endpoint definition, log-rank analysis, hazard ratio, confidence interval, p-value, and…
- DIRECTComplete statistical analysis of the DIRECT phase 3 trial of candesartan in participants with type 1 diabetes, including trial design, diabetic retinopathy progression, time-to-event methodology, hazard ratio interpretation, and safety.
- DIRECTComplete statistical analysis of the DIRECT trial of candesartan versus placebo in type 1 diabetes, including trial design, ETDRS retinopathy endpoint, log-rank analysis, hazard ratio, confidence interval, p-value, safety, and statistical interpretation.
- DIRECTComplete statistical analysis of DIRECT, a randomized phase 3 trial of denosumab versus placebo in Japanese patients with osteoporosis, including vertebral fracture, non-vertebral fracture, and hip fracture analyses.
- DOC-MEKIndependent statistical analysis of Docetaxel With or Without AZD6244 in Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01256359).
- Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC): Complete Statistical AnalysisIndependent statistical analysis of Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC): primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder: Complete Statistical AnalysisIndependent statistical analysis of Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01382706).
- Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency: Complete Statistical AnalysisIndependent statistical analysis of Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency: primary endpoint results, effect estimate with confidence interval,…
- Docetaxel, Cisplatin, and Fluorouracil Followed By Cetuximab and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer: Complete Statistical AnalysisIndependent statistical analysis of Docetaxel, Cisplatin, and Fluorouracil Followed By Cetuximab and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer: primary endpoint results, effect estimate with confidence interval,…
- Donor Umbilical Cord Blood Transplant By Injection Into the Bone Marrow in Treating Patients With Hematologic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Donor Umbilical Cord Blood Transplant By Injection Into the Bone Marrow in Treating Patients With Hematologic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures: Complete Statistical AnalysisIndependent statistical analysis of Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- DREAMM-3Independent statistical analysis of DREAMM-3, a randomized phase 3 trial comparing single-agent belantamab mafodotin with pomalidomide plus low-dose dexamethasone in relapsed/refractory multiple myeloma.
- DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]: Complete Statistical AnalysisIndependent statistical analysis of DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]: primary endpoint results, effect estimate…
- DYNAGITOIndependent statistical analysis of DYNAGITO (NCT02296138), a phase 3 trial of tiotropium/olodaterol 5/5 µg versus tiotropium 5 µg for moderate to severe COPD exacerbations: negative binomial rate ratios, 99% confidence intervals, a…
- e3Complete statistical analysis of the e3 phase 3 trial evaluating everolimus versus placebo with hormone therapy in breast cancer, including trial design, time-to-event endpoints, hazard ratios, confidence intervals, statistical methodology, and interpretation.
- Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- ECHELON-2Independent statistical analysis of ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas: primary endpoint results, effect estimate with confidence…
- Effect of 2-h Infusion of ON 01910.Na in Ovarian Cancer Patients: Complete Statistical AnalysisIndependent statistical analysis of Effect of 2-h Infusion of ON 01910.Na in Ovarian Cancer Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…